Salipro Biotech and Boehringer Ingelheim Collaborate on Drug Development for Membrane Proteins
Sweden-based Salipro Biotech AB announced a research and license agreement with German pharmaceutical giant Boehringer...
Boehringer Ingelheim
Boehringer Ingelheim Launches One Medicine Platform with Veeva’s Development Cloud
German pharmaceutical giant Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) announced the successful launch of...
Sino Biopharmaceutical Licenses Nanjing Delova’s QP001 for Mainland China Rights
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced acquiring exclusive rights to Nanjing Delova Biotech Co.,Ltd’s...
Boehringer Ingelheim Appeals CNIPA’s Invalidation of Jardiance Patents
The Intellectual Property Court of the Supreme People’s Court of China issued a notice, holding...
Boehringer Ingelheim’s Nerandomilast Receives NMPA Review for IPF Treatment
Boehringer Ingelheim announced that its investigational drug nerandomilast has been accepted for review by the...
Boehringer Ingelheim Launches LENTICLAIR Study for CF Gene Therapy BI 3720931
German pharmaceutical company Boehringer Ingelheim announced the initiation of the Phase I/II LENTICLAIR study for...
Boehringer Ingelheim’s Zongertinib NDA Accepted by FDA for HER2-Mutated NSCLC
Germany-based Boehringer Ingelheim announced that the US Food and Drug Administration (FDA) has accepted its...
Boehringer Ingelheim’s Nerandomilast Hits Primary Endpoint in PPF Phase III Study
German pharma giant Boehringer Ingelheim announced positive topline results from the Phase III FIBRONEER-ILD study...
Boehringer Ingelheim’s Nerandomilast Granted Priority Review for IPF in China
German pharmaceutical giant Boehringer Ingelheim has announced that the Center for Drug Evaluation (CDE) of...
Boehringer Ingelheim’s Iclepertin Fails to Meet Phase III Study Endpoints
German giant Boehringer Ingelheim has disclosed negative top-line results from the Phase III CONNEX study...
Suzhou Ribo and Boehringer Ingelheim Reach Pre-Clinical Milestone in NASH/MASH Partnership
China-based Suzhou Ribo Life Science Co., Ltd has announced the achievement of a first pre-clinical...
Boehringer Ingelheim Licenses ADC Technology from Synaffix to Boost Portfolio
German giant Boehringer Ingelheim has announced the licensing of antibody drug conjugate (ADC) technology from...
Boehringer Ingelheim and Sutro Achieve Commercial-Scale Manufacturing of Luvelta
Boehringer Ingelheim BioXcellence and Sutro Biopharma Inc. have announced the successful application of Sutro’s proprietary...
Boehringer Ingelheim China and Shanghai Pharmaceuticals Holding Co. Launch Strategic Partnership for Linagliptin
On January 7, Boehringer Ingelheim China and Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607,...
CDE Indicates Priority Review for Boehringer Ingelheim’s Zongertinib and Peers
The China’s Center for Drug Evaluation (CDE) website has indicated that several drugs, including German...
Boehringer Ingelheim-SEC Joint Incubator Launches in Shenzhen’s Luohu District
On December 23, the Boehringer Ingelheim-SEC Joint innovative incubator was inaugurated in Luohu District, Shenzhen....
Guardant Health and Boehringer Ingelheim Join Forces to Develop Guardant360 CDx for Zongertinib Companion Diagnostic
US-based precision oncology specialist Guardant Health, Inc. (NASDAQ: GH) has entered into an agreement with...
BI Partners with Sinopharm for Promotion of Sifrol and Pradaxa in China
German pharmaceutical major Boehringer Ingelheim (BI) has entered into a partnership with China-based Sinopharm Group...
Boehringer Ingelheim Joins MTM Vision Consortium to Advance Diabetes Retinopathy Research
Germany-based pharmaceutical major Boehringer Ingelheim has announced the initiation of a long-term collaboration with the...
Boehringer Ingelheim Partners with Wuhan Union Hospital to Enhance Clinical Research and Development
Boehringer Ingelheim, a leading German pharmaceutical company, has entered into a strategic partnership with Wuhan...